Bionomics Results Presentation Deck

Next steps 2023 is a pivotal year for Bionomics Request and conduct FDA End-of-Phase 2 Meeting by Q3 2023 to discuss the registrational program design Initiate start-up activities for Ph3 study execution targeting First Patient In in late 2023-early 2024 Kick-off financing and partnering discussions Initiate Bionomics' transformation into a late-clinical stage company with enhanced US focus Continue execution of PTSD program targeting a read-out in mid 2023 Continue partnering discussions for Company's preclinical assets (KV3 and PanNav programs) and Merck Collaboration Bionomics

View entire presentation